Disease or Syndrome – Page 4

Arcturus Therapeutics Stock Crashes 60% on Underwhelming mRNA Cystic Fibrosis Drug Results

2 weeks ago talkbio0Tagged ARCT-032, Arcturus Therapeutics ', clinical trial results, Cystic Fibrosis, mRNA therapy, Respiratory physiology, safety profile, Stock Crash, Volume^at 1.0 s post forced expiration:Volume:Point in time:Respiratory system:Quantitative

Arcturus Therapeutics; ARCT-032; cystic fibrosis; mRNA therapy; stock crash; clinical trial results; lung function; FEV1; safety profile

Alkermes Acquires Avadel Pharmaceuticals for $2.1B, Gaining Sleep Drug LUMRYZ and Setting Strategic Evolution

2 weeks ago talkbio0Tagged Acquisition, Alkermes, Avadel Pharmaceuticals, Biological Factors, LUMRYZ, Narcolepsy, portfolio, premium, Rare Diseases, Sleep medicine specialist, strategic

Alkermes; Avadel Pharmaceuticals; acquisition; LUMRYZ; narcolepsy; sleep medicine; strategic portfolio; biopharmaceuticals; rare disease; deal premium

Terns Ditches Obesity Pill After Phase 2 Letdown, Shifts Focus to Cancer Pipeline

2 weeks ago talkbio0Tagged liver enzyme elevation, Metabolic Diseases, Myeloid Leukemia, Chronic, Neoplasms, Obesity Drug, Phase 2 trial, Product containing glucagon-like peptide 1 receptor agonist (product), TERN-601, TERN-701, Terns, Weight Loss

Terns Pharmaceuticals; TERN-601; obesity drug; GLP-1 receptor agonist; Phase 2 trial; weight loss; liver enzyme elevation; oncology; TERN-701; chronic myeloid leukemia (CML); metabolic disease

Sanofi’s efdoralprin alfa (INBRX-101) achieves all endpoints in Phase 2 alpha-1 antitrypsin deficiency (AATD) trial

2 weeks ago talkbio0Tagged Acquisition, alpha 1-Antitrypsin Deficiency, efdoralprin alfa, INBRX-101, Inhibrx, Phase 2, plasma-derived therapy, Rare Diseases, sanofi, Zemaira

Sanofi; efdoralprin alfa; INBRX-101; AATD; alpha-1 antitrypsin deficiency; Phase 2; Inhibrx; acquisition; rare disease; plasma-derived therapy; Zemaira

Alector’s GSK-partnered dementia drug latozinemab fails in late-stage trial

2 weeks ago talkbio0Tagged Alector, Clinical trial failure, Drug Development, Latozinemab, Phase 3 trial, Pick Disease of the Brain, Presenile dementia, Progranulins, SmithKline Beecham

Alector; GSK; latozinemab; dementia; frontotemporal dementia; Phase 3 trial; clinical trial failure; progranulin; drug development

Elevara Raises $70M to Advance Novel Rheumatoid Arthritis Treatment Targeting Synovial Fibroblasts

2 weeks ago talkbio0Tagged CDK4/6 inhibitor, Chronic inflammatory disorder, Clinical Trials, Elevara Medicines, ELV001, Forbion, Partner in relationship, Pharma, Rheumatoid Arthritis, Series A financing, Sofinnova, synovial fibroblasts, Teijin

Elevara Medicines; Series A financing; rheumatoid arthritis; ELV001; CDK4/6 inhibitor; synovial fibroblasts; Teijin Pharma; clinical trial; chronic inflammatory diseases; Forbion; Sofinnova Partners

GSK, Spero Reveal Full Phase 3 Data for Oral Antibiotic Tebipenem HBr; Regulatory Filing Set for End of 2025

2 weeks ago talkbio0Tagged Complicated, cUTIs, HBr, IDWeek, non-inferiority, oral carbapenem, Phase 3 PIVOT-PO trial, Regulatory Filing, SmithKline Beecham, Spero Therapeutics, Submission, United States Food and Drug Administration, Urinary tract infection

GSK; Spero Therapeutics; tebipenem HBr; oral carbapenem; Phase 3 PIVOT-PO trial; complicated urinary tract infections (cUTIs); non-inferiority; IDWeek 2025; regulatory filing; FDA submission

Epiminder Appoints Mark McLellan as Chief Financial Officer

2 weeks ago talkbio0Tagged Appointments, authorization, CFO, Epilepsy, Epiminder, healthcare finance, Mark McLellan, medical device company, Minder system, Preventive monitoring, United States Food and Drug Administration

Epiminder; Mark McLellan; CFO appointment; epilepsy monitoring; Minder system; FDA authorization; healthcare finance; medical device company

Companies Struggle to Accelerate Production of Bespoke mRNA Therapies

2 weeks ago talkbio0Tagged bespoke, Cancer Vaccines, cold chain logistics, Efficiency, innovation, Manufacturing, manufacturing challenges, mRNA production, mRNA therapies, Optimization, Precision Medicine, regulatory complexity, scalability

bespoke mRNA therapies; personalized medicine; manufacturing challenges; cancer vaccines; scalability; manufacturing efficiency; cold chain logistics; regulatory complexity; mRNA production innovation; AI optimization

Replimune Resubmits Melanoma Drug for FDA Approval After Initial Rejection

2 weeks ago talkbio0Tagged Approved, melanoma, Replimune, resubmission, RETINITIS PIGMENTOSA 1, United States Food and Drug Administration

Replimune; RP1; Melanoma Treatment; FDA Approval; Resubmission